Oppenheimer & Co’s Ocular Therapeutix OCUL Stock Holding History

Oppenheimer & Co’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,855	Closed	-$180K	–	1764
2025 Q4	$180K	Buy	+14,855	New	+$180K	﹤0.01%	1449

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Oppenheimer & Co's OCUL Position: Q1 2026 in Review

Oppenheimer & Co sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 14,855 shares — an estimated $180K sold.

Oppenheimer & Co first reported a position in OCUL in Q4 2025 and held it in 1 quarter. The position peaked at $180K in Q4 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Oppenheimer & Co reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
Oppenheimer & Co sold 14,855 Ocular Therapeutix shares in Q1 2026, an estimated $180K.
Oppenheimer & Co first reported a position in Ocular Therapeutix in Q4 2025 and held it in 1 quarter.
Oppenheimer & Co's Ocular Therapeutix position peaked at $180K in Q4 2025.
271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.